The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
one of the most promising versions of these monoclonal antibodies to amyloid is atacanamab which is a drug manufactured by a company called biogen and it's been in the news a lot lately um i think for several reasons one is a drug that made it to phase three and it was running two parallel studies uh emerge and what was the other one called engage yeah so and to my understanding very little difference between them
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
one of the most promising versions of these monoclonal antibodies to amyloid is atticanam which is a drug manufactured by a company called biogen and it's been in the news a lot lately i think for several reasons one is a drug that made it to phase three and it was running two parallel studies uh what emerge and what was the other one called engage yeah so and to my understanding very little difference between them